Ajanta Pharma Ltd Stock Price Today (NSE: AJANTPHARM)
Fundamental Score
Ajanta Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ajanta Pharma Ltd share price today is ₹2805.10, down 2.50% on NSE/BSE as of 30 March 2026. Ajanta Pharma Ltd (AJANTPHARM) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹32.08K (Cr). The 52-week high for AJANTPHARM share price is ₹3228.00 and the 52-week low is ₹2327.30. At a P/E ratio of 32.94x, AJANTPHARM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 24.91% and a debt-to-equity ratio of 0.06.
Ajanta Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Ajanta Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Ajanta Pharma Share Price: A ROCE-Driven Financial Analysis
The pharmaceutical industry, facing increasing regulatory scrutiny and evolving patient needs, demands operational excellence for sustained profitability. This analysis examines the financial health of Ajanta Pharma Ltd, focusing on its Return on Capital Employed (ROCE). Currently, the Ajanta Pharma share price stands at ₹2852.699951, with a Price-to-Earnings (PE) ratio of 32.94 and an impressive ROCE of 32.37%. This analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra.
A key strength of Ajanta Pharma appears to be its exceptional ROCE. A 32.37% ROCE suggests that Ajanta Pharma is generating significant profit from its capital employed. This high efficiency provides a considerable competitive advantage, contributing to the company's economic moat. The consistent generation of high returns on invested capital allows the company to reinvest in research and development, expand its market reach, and potentially increase shareholder value.
When evaluating Ajanta Pharma Ltd, it's crucial to consider its position relative to its peers. Competitors such as Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd operate within the same industry landscape. Examining the relative management quality between companies, we can observe that
Mankind Pharma Ltd have different management strategies. The differences in management strategies and ROCE figures can indicate different approaches to capital allocation and operational efficiency, ultimately influencing long-term performance. For example, one can consider the ratio of operational expenses with net sales.While the PE ratio of 32.94 may appear high, it is important to remember that it reflects market expectations for future growth and profitability. Investors might be willing to pay a premium for Ajanta Pharma due to its demonstrated ability to generate high returns on capital, signifying a strong competitive position and efficient management. Further investigation into Ajanta Pharma's debt levels, cash flow generation, and pipeline of new products would offer a more comprehensive understanding of its long-term financial outlook.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ajanta Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AJANTPHARM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (24.91%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (32.37%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (27.53%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (20.19%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (12.43% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (15.34% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (56.18x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹2953.50 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (66.24%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 26.43%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Ajanta Pharma Ltd Financial Statements
Comprehensive financial data for Ajanta Pharma Ltd including income statement, balance sheet and cash flow
About AJANTPHARM (Ajanta Pharma Ltd)
Ajanta Pharma Ltd is a dynamic pharmaceutical company committed to developing and delivering innovative healthcare solutions across a diverse range of therapeutic areas. With a foc...us on specialty pharmaceutical formulations, Ajanta Pharma blends scientific expertise with cutting-edge manufacturing processes to create high-quality medicines designed to address unmet medical needs. The company's product portfolio encompasses a broad spectrum of dosage forms, from conventional tablets and capsules to advanced injectables and inhalers, reflecting its dedication to providing versatile treatment options for patients. Ajanta Pharma's unwavering pursuit of excellence drives its commitment to research and development, enabling it to consistently introduce novel products that improve patient outcomes and enhance the quality of life. Ajanta Pharma's strategic approach to the pharmaceutical market involves a dual focus on chronic and acute therapies, catering to both long-term health management and immediate medical interventions. This comprehensive strategy allows the company to address a wide range of patient needs and contribute to overall healthcare advancement. The company's branded generic products are recognized for their reliability and affordability, making essential medications accessible to a broader population. Ajanta Pharma's dedication to quality extends beyond its product offerings, encompassing rigorous quality control measures throughout the entire manufacturing process, ensuring that every medicine meets the highest standards of safety and efficacy. Ajanta Pharma operates with a global vision, serving diverse therapeutic areas such as cardiology, dermatology, ophthalmology, and pain management. This diversified approach enables the company to navigate the complexities of the pharmaceutical landscape and adapt to evolving healthcare needs. By consistently investing in research and innovation, Ajanta Pharma strives to be at the forefront of pharmaceutical advancements, developing solutions that address critical health challenges worldwide. The company's commitment to ethical business practices and patient-centric values underpins its mission to improve health outcomes and make a positive impact on communities worldwide.
Company Details
Key Leadership
Corporate Events
AJANTPHARM Share Price: Frequently Asked Questions
What is the current share price of Ajanta Pharma Ltd (AJANTPHARM)?
As of 30 Mar 2026, 12:07 pm IST, Ajanta Pharma Ltd share price is ₹2805.10. The AJANTPHARM stock has a market capitalisation of ₹32.08K (Cr) on NSE/BSE.
Is AJANTPHARM share price Overvalued or Undervalued?
AJANTPHARM share price is currently trading at a P/E ratio of 32.94x, compared to the industry average of 31.77x. Based on this relative valuation, the Ajanta Pharma Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of AJANTPHARM share price?
The 52-week high of AJANTPHARM share price is ₹3228.00 and the 52-week low is ₹2327.30. These values are updated daily from NSE/BSE price data.
What factors affect the Ajanta Pharma Ltd share price?
Key factors influencing AJANTPHARM share price include quarterly earnings growth (Sales Growth: 14.08%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Ajanta Pharma Ltd a good stock for long-term investment?
Ajanta Pharma Ltd shows a 5-year Profit Growth of 14.26% and an ROE of 24.91%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.06 before investing in AJANTPHARM shares.
How does Ajanta Pharma Ltd compare with its industry peers?
Ajanta Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare AJANTPHARM share price P/E of 32.94x and ROE of 24.91% against the industry averages to determine competitive standing.
What is the P/E ratio of AJANTPHARM and what does it mean?
AJANTPHARM share price has a P/E ratio of 32.94x compared to the industry average of 31.77x. Investors pay ₹33 for every ₹1 of annual earnings.
How is AJANTPHARM performing according to Bull Run's analysis?
AJANTPHARM has a Bull Run fundamental score of 53.5/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does AJANTPHARM belong to?
AJANTPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Ajanta Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for AJANTPHARM?
AJANTPHARM has an ROE of 24.91%, which indicates excellent management efficiency. ROE measures how efficiently Ajanta Pharma Ltd generates profits from shareholders capital.
How is AJANTPHARM debt-to-equity ratio and what does it indicate?
AJANTPHARM has a debt-to-equity ratio of 0.06, which indicates conservative financing with low financial risk.
What is AJANTPHARM dividend yield and is it a good dividend stock?
AJANTPHARM offers a dividend yield of 1.09%, meaning you receive ₹1.09 annual dividend for every ₹100 invested in Ajanta Pharma Ltd shares.
How has AJANTPHARM share price grown over the past 5 years?
AJANTPHARM has achieved 5-year growth rates of: Sales Growth 12.43%, Profit Growth 14.26%, and EPS Growth 15.34%.
What is the promoter holding in AJANTPHARM and why does it matter?
Promoters hold 66.24% of AJANTPHARM shares, with 15.28% pledged. High promoter holding often indicates strong management confidence in Ajanta Pharma Ltd.
What is AJANTPHARM market capitalisation category?
AJANTPHARM has a market capitalisation of ₹32076 crores, placing it in the Large-cap category.
How volatile is AJANTPHARM stock?
AJANTPHARM has a beta of N/A. A beta > 1 suggests the Ajanta Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is AJANTPHARM operating profit margin trend?
AJANTPHARM has a 5-year average Operating Profit Margin (OPM) of 27.53%, indicating the company's operational efficiency.
How is AJANTPHARM quarterly performance?
Recent quarterly performance shows Ajanta Pharma Ltd YoY Sales Growth of 14.08% and YoY Profit Growth of 20.19%.
What is the institutional holding pattern in AJANTPHARM?
AJANTPHARM has FII holding of 8.53% and DII holding of 17.90%. Significant institutional holding often suggests professional confidence in the Ajanta Pharma Ltd stock.